Mauritius-based holding company Aspen Global Incorporated (AGI) has signed an agreement with AstraZeneca to acquire the rights to the latter’s anaesthetic treatments portfolio for $555m.

AstraZeneca will receive performance-related milestones of up to $211m from AGI between 1 September 2017 and 30 November 2019. The company will also produce the anaesthetic treatments during the transition period.

The divestment will improve the efficiencies of both companies.

Chinese pharmaceutical company Zhejiang Conba Pharmaceutical plans to raise CNY1.5bn ($228.81m) through a public offering of medium-term notes.

The company plans to use the funds for working capital purposes.

"Chinese pharmaceutical company Zhejiang Conba Pharmaceutical plans to raise CNY1.5bn ($228.81m) through a public offering of medium-term notes."

Israeli pharmaceutical company Teva Pharmaceutical Industries has signed an agreement with US-based pharmaceutical company Nuvelution Pharma to develop AUSTEDO (deutetrabenazine) tablets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nuvelution Pharma will handle the clinical development of the drug, while Teva Pharma will be responsible for the regulatory process and commercialisation, under the agreement.

Chinese pharmaceutical products manufacturer Kangmei Pharmaceutical has announced the completion of the third tranche of a public offering of 5.47% medium-term notes due 2022 to raise CNY2bn ($304.74m).

Chinese pharmaceutical company Zhejiang Huahai Pharmaceutical plans to raise CNY1.8bn ($274.6m) through a public offering of convertible bonds due 2023.